See more : Oxford Lane Capital Corp. (OXLC) Income Statement Analysis – Financial Results
Complete financial analysis of OraSure Technologies, Inc. (OSUR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OraSure Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Gruppo MutuiOnline S.p.A (0O2B.L) Income Statement Analysis – Financial Results
- Lion One Metals Limited (LOMLF) Income Statement Analysis – Financial Results
- Firan Technology Group Corporation (FTG.TO) Income Statement Analysis – Financial Results
- Echo Global Logistics, Inc. (ECHO) Income Statement Analysis – Financial Results
- Sunrise Communications AG (SNREV) Income Statement Analysis – Financial Results
OraSure Technologies, Inc. (OSUR)
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 405.47M | 387.48M | 233.67M | 171.72M | 154.61M | 181.74M | 167.06M | 128.20M | 119.72M | 106.46M | 98.94M | 87.82M | 81.88M | 75.02M | 77.03M | 71.10M | 82.69M | 68.15M | 69.37M | 54.01M | 40.45M | 32.01M | 32.57M | 30.10M | 10.10M | 9.80M | 9.40M | 68.70M | 5.00M | 4.80M | 3.30M | 3.00M | 3.80M | 3.60M | 3.20M |
| Cost of Revenue | 226.05M | 239.84M | 116.07M | 69.85M | 60.02M | 68.13M | 68.11M | 40.17M | 39.43M | 39.84M | 40.35M | 32.25M | 30.16M | 27.66M | 29.90M | 29.98M | 32.40M | 24.76M | 27.97M | 22.14M | 16.06M | 12.89M | 12.33M | 9.00M | 3.10M | 3.00M | 2.80M | 58.60M | 4.90M | 5.60M | 1.70M | 1.20M | 1.90M | 2.00M | 4.20M |
| Gross Profit | 179.42M | 147.64M | 117.60M | 101.87M | 94.58M | 113.61M | 98.96M | 88.03M | 80.29M | 66.62M | 58.59M | 55.57M | 51.72M | 47.36M | 47.13M | 41.13M | 50.28M | 43.40M | 41.39M | 31.87M | 24.39M | 19.12M | 20.24M | 21.10M | 7.00M | 6.80M | 6.60M | 10.10M | 100.00K | -800.00K | 1.60M | 1.80M | 1.90M | 1.60M | -1.00M |
| Gross Profit Ratio | 44.25% | 38.10% | 50.33% | 59.32% | 61.18% | 62.51% | 59.23% | 68.66% | 67.07% | 62.58% | 59.22% | 63.28% | 63.16% | 63.13% | 61.19% | 57.84% | 60.81% | 63.68% | 59.67% | 59.00% | 60.29% | 59.74% | 62.14% | 70.10% | 69.31% | 69.39% | 70.21% | 14.70% | 2.00% | -16.67% | 48.48% | 60.00% | 50.00% | 44.44% | -31.25% |
| Research & Development | 33.73M | 36.24M | 34.17M | 31.03M | 19.63M | 16.25M | 13.37M | 9.75M | 11.65M | 12.06M | 10.93M | 12.45M | 18.41M | 13.19M | 13.37M | 20.26M | 14.14M | 8.65M | 5.27M | 6.06M | 8.00M | 8.27M | 9.39M | 10.40M | 4.00M | 2.90M | 4.20M | 4.50M | 6.80M | 6.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 58.19M | 68.21M | 50.33M | 42.65M | 35.29M | 38.33M | 29.32M | 28.36M | 25.49M | 23.75M | 21.65M | 22.31M | 20.33M | 16.79M | 18.30M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 36.32M | 49.24M | 44.75M | 34.46M | 31.87M | 30.61M | 28.53M | 29.65M | 35.09M | 41.12M | 46.47M | 37.09M | 22.38M | 20.73M | 21.22M | 20.92B | 20.06B | 15.92B | 16.06B | 15.15B | 10.76B | 8.07B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 92.18M | 117.44M | 95.08M | 77.11M | 67.16M | 68.93M | 57.85M | 58.01M | 60.58M | 64.87M | 68.12M | 59.40M | 42.71M | 37.52M | 39.52M | 37.20M | 37.37M | 29.29M | 28.55M | 27.16M | 17.68M | 14.39M | 14.73M | 13.81M | 5.70M | 5.40M | 6.70M | 9.80M | 11.20M | 7.80M | 13.90M | 8.20M | 6.10M | 4.40M | 1.40M |
| Other Expenses | 0.00 | 6.48M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| Operating Expenses | 146.74M | 153.68M | 129.25M | 108.14M | 86.79M | 85.18M | 71.22M | 67.76M | 72.24M | 76.93M | 79.05M | 71.84M | 61.12M | 50.71M | 52.89M | 57.46M | 51.50M | 37.94M | 33.82M | 33.22M | 25.68M | 22.66M | 24.12M | 26.31M | 10.40M | 9.00M | 11.60M | 15.60M | 19.50M | 15.10M | 15.00M | 9.40M | 7.00M | 4.90M | 1.70M |
| Cost & Expenses | 372.79M | 393.52M | 245.32M | 178.00M | 146.81M | 153.31M | 139.33M | 107.93M | 111.66M | 116.77M | 119.40M | 104.09M | 91.28M | 78.37M | 82.79M | 87.44M | 83.91M | 62.69M | 61.79M | 55.36M | 41.74M | 35.55M | 36.46M | 35.31M | 13.50M | 12.00M | 14.40M | 74.20M | 24.40M | 20.70M | 16.70M | 10.60M | 8.90M | 6.90M | 5.90M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.99K | 151.76K | 737.89K | 3.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 10.43M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 172.00K | 316.31K | 316.19K | 361.19K | 345.77K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.94M | 14.00M | 11.66M | 9.39M | 7.34M | 6.45M | 6.40M | 5.69M | 5.70M | 6.31M | 6.49M | 7.25M | 4.89M | 3.01M | 3.05M | 3.39M | 2.74M | 1.92M | 2.35M | 2.49M | 2.58M | 2.18M | 2.00M | 2.10M | 700.00K | 700.00K | 700.00K | 1.30M | 1.50M | 1.20M | 1.10M | 1.20M | 900.00K | 500.00K | 300.00K |
| EBITDA | 64.35M | 10.29M | 9.00K | 3.44M | 15.53M | 34.88M | 34.14M | 26.01M | 8.06M | -4.00M | -13.91M | -9.09M | -4.50M | -168.49K | -5.02M | -5.02M | 1.52M | 7.39M | 9.92M | 1.13M | 1.29M | -1.36M | -1.89M | -4.42M | -2.70M | -1.50M | -4.30M | -4.20M | -10.10M | -14.70M | -12.30M | -6.40M | -4.20M | -2.80M | -2.40M |
| EBITDA Ratio | 15.87% | 2.81% | -5.62% | -4.29% | 3.05% | 19.62% | 12.95% | 15.81% | 11.49% | -8.92% | -22.51% | -10.27% | -11.10% | -4.28% | -2.57% | -25.02% | 0.23% | 10.98% | 14.22% | 2.19% | 3.34% | -4.25% | -4.73% | 13.02% | -26.73% | -19.39% | -54.26% | -13.97% | -376.00% | -308.33% | -333.33% | -223.33% | -115.79% | -88.89% | -81.25% |
| Operating Income | 54.08M | -4.67M | -11.65M | -6.28M | -3.02M | 28.43M | 40.24M | 20.27M | 8.06M | -4.80M | -12.16M | -16.27M | -9.40M | -3.35M | -8.79M | -16.33M | -1.22M | 5.46M | 7.57M | -1.36M | -1.29M | -3.54M | -4.33M | -12.81M | -3.40M | -2.20M | -5.00M | -5.50M | -19.40M | -15.90M | -13.40M | -7.60M | -5.10M | -3.30M | -2.70M |
| Operating Income Ratio | 13.34% | -1.20% | -4.99% | -3.65% | -1.95% | 15.64% | 24.09% | 15.81% | 6.73% | -4.51% | -12.29% | -18.53% | -11.48% | -4.47% | -11.42% | -22.97% | -1.47% | 8.02% | 10.92% | -2.51% | -3.18% | -11.06% | -13.30% | -42.56% | -33.66% | -22.45% | -53.19% | -8.01% | -388.00% | -331.25% | -406.06% | -253.33% | -134.21% | -91.67% | -84.38% |
| Total Other Income/Expenses | 2.18M | -9.63M | 872.00K | 1.65M | 2.72M | 3.29M | 794.00K | 58.00K | 774.00K | 531.00K | 200.00K | -242.00K | -312.57K | -142.84K | 357.15K | 7.58M | 5.51M | 3.60M | 2.15M | 797.04K | 176.80K | 198.06K | 633.49K | 90.89K | 200.00K | 400.00K | 800.00K | 5.00M | 11.60M | 100.00K | -1.30M | 300.00K | 200.00K | 400.00K | 200.00K |
| Income Before Tax | 56.26M | -16.48M | -9.29M | -3.52M | 21.33M | 31.72M | 41.03M | 20.32M | 8.83M | -4.27M | -11.96M | -16.51M | -9.71M | -3.50M | -8.44M | -8.75M | 4.29M | 9.06M | 9.72M | -559.64K | -1.11M | -3.34M | -3.70M | -12.72M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Income Before Tax Ratio | 13.87% | -4.25% | -3.98% | -2.05% | 13.80% | 17.45% | 24.56% | 15.85% | 7.38% | -4.01% | -12.09% | -18.80% | -11.86% | -4.66% | -10.95% | -12.30% | 5.19% | 13.30% | 14.01% | -1.04% | -2.74% | -10.44% | -11.36% | -42.26% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| Income Tax Expense | 2.60M | 1.46M | 13.71M | 11.40M | 4.68M | 11.32M | 10.08M | 603.00K | 665.00K | 343.00K | -772.00K | -1.40M | -869.00K | 142.84K | -622.28K | 22.53M | 1.82M | 3.79M | -17.73M | -797.04K | 26.59K | -198.06K | 28.79K | 24.36K | 3.20M | 1.90M | 22.50M | 300.00K | 18.50M | 15.60M | 14.70M | 7.20M | 4.90M | 2.90M | 2.60M |
| Net Income | 53.66M | -17.94M | -23.00M | -14.92M | 16.66M | 20.40M | 30.95M | 19.72M | 8.17M | -4.61M | -11.19M | -15.12M | -8.84M | -3.50M | -7.81M | -31.28M | 2.47M | 5.27M | 27.45M | -559.64K | -1.14M | -3.34M | -3.73M | -12.75M | -3.20M | -1.90M | -22.50M | -300.00K | -18.50M | -15.60M | -14.70M | -7.20M | -4.90M | -2.90M | -2.60M |
| Net Income Ratio | 13.23% | -4.63% | -9.84% | -8.69% | 10.77% | 11.22% | 18.52% | 15.38% | 6.82% | -4.33% | -11.31% | -17.21% | -10.80% | -4.66% | -10.14% | -43.99% | 2.99% | 7.73% | 39.57% | -1.04% | -2.81% | -10.44% | -11.44% | -42.34% | -31.68% | -19.39% | -239.36% | -0.44% | -370.00% | -325.00% | -445.45% | -240.00% | -128.95% | -80.56% | -81.25% |
| EPS | 0.73 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.52 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.61 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| EPS Diluted | 0.72 | -0.25 | -0.32 | -0.22 | 0.27 | 0.33 | 0.51 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | -0.17 | -0.67 | 0.05 | 0.11 | 0.59 | -0.01 | -0.03 | -0.09 | -0.10 | -0.36 | -0.23 | -0.14 | -1.12 | -0.02 | -1.04 | -1.07 | -1.11 | -0.55 | -0.43 | -0.29 | -0.31 |
| Weighted Avg Shares Out | 73.35M | 72.51M | 71.98M | 67.51M | 61.68M | 61.11M | 59.05M | 55.62M | 56.40M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.33M | 45.91M | 45.11M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
| Weighted Avg Shares Out (Dil) | 74.39M | 72.51M | 71.98M | 67.51M | 62.17M | 62.53M | 61.02M | 56.51M | 56.85M | 55.95M | 55.56M | 51.46M | 46.91M | 46.19M | 45.88M | 46.55M | 46.88M | 46.58M | 46.15M | 44.46M | 39.79M | 37.58M | 36.87M | 35.00M | 13.91M | 13.57M | 20.10M | 18.90M | 17.79M | 14.61M | 13.24M | 13.09M | 11.40M | 10.00M | 8.39M |
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for...
Is OraSure Technologies (OSUR) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
OraSure to Participate in Upcoming Investor Conference
BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference:
Is OraSure Technologies (OSUR) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q3 2024 Earnings Call Transcript
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
OraSure Technologies (OSUR) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.27 per share a year ago.
OraSure Reports Q3 '24 Revenue of $39.9 Million
Q3 GAAP EPS of $(0.06) ; Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with...
OraSure: An NCAV Diamond In The COVID Rough
OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value (NCAV). At the same time, OraSure...
OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th
BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024.
Neuberger Berman Group LLC Expands Stake in OraSure Technologies Inc
On September 30, 2024, Neuberger Berman Group LLC, a prominent investment firm, made a significant addition to its investment portfolio by acquiring 3,927,692 shares of OraSure Technologies Inc (OSUR, Financial). This transaction, executed at a price of $4.27 per share,...
Source: https://incomestatements.info
Category: Stock Reports